Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Generic challenges, the next first-to-files, GDUFA dues (FY 2016) and more
PharmaCompass has assessed the second quarter US Drug Master
File (DMFs) filings. In our view, with
